New 'Self-Vaccine' injection tested to fight skin cancer before surgery
NCT ID NCT06014086
Summary
This early-stage study is testing the safety of a new drug called PH-762, which is injected directly into a single skin cancer tumor. The goal is to see if stimulating the immune system locally can help shrink the tumor before it is surgically removed. The study is for adults with certain types of advanced skin cancer (squamous cell carcinoma, melanoma, or Merkel cell carcinoma) that have not responded well to other treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF THE SKIN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Banner MD Anderson Cancer Center
Gilbert, Arizona, 85234, United States
-
Centricity Research
Columbus, Ohio, 43213, United States
-
Integrity Research
Delray Beach, Florida, 33445, United States
-
Paradigm Clinical Research
San Diego, California, 92108, United States
-
Skin Cancer and Dermatology Institute
Reno, Nevada, 89509, United States
Conditions
Explore the condition pages connected to this study.